The process of consensus update was sponsored by the Prosperous Foundation, Taipei, Taiwan, who received unrestricted grants from GSK, Roche, BMS and Sciclone.
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
Article first published online: 21 MAY 2005
Volume 25, Issue 3, pages 472–489, June 2005
How to Cite
Liaw, Y.-F., Leung, N., Guan, R., Lau, G. K.K., Merican, I., McCaughan, G., Gane, E., Kao, J.-H., Omata, M. and for the Asian-Pacific consensus update working party on chronic hepatitis B (2005), Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver International, 25: 472–489. doi: 10.1111/j.1478-3231.2005.01134.x
Other members of the working party, consensus update on chronic hepatitis B. A. Chutaputti (Thailand), D. S. Chen (Taiwan), R. N. Chien (Taiwan), G. Cooksley (Australia), K. H. Han (Korea), T. Ichida (Japan), M. Y. Lai (Taiwan), L. Lesmana (Indonesia), T. Piratvisuth (Thailand), S. K. Sarin (India), J. Sollano (Philippines), D. J. Suh (Korea), G. B. Yao (China), C. T. Yeh (Taiwan), O. Yokosuka (Japan).
- Issue published online: 21 MAY 2005
- Article first published online: 21 MAY 2005
- Received 19 January 2005, accepted 15 March 2005
- chronic hepatitis B;
- hepatic decompensation;
- liver transplantation
Background/Aims: A large amount of new data on the treatment of chronic hepatitis B has become available such that the 2003 consensus statement requires revision and update.
Methods: New data were presented, discussed and debated in an expert pre-meeting to draft a revision. The revised contents were finalized after discussion in a general meeting of APASL.
Results: Conceptual background, including the efficacy and safety profile of currently available and emerging drugs, was reviewed. Nineteen recommendations were formed and unresolved issues and areas for further study were suggested.
Conclusion: The current therapy of chronic hepatitis B is modestly effective but not satisfactory. The development of new drugs and new strategies is required to further improve the outcomes of treatment.